Samsara BioCapital LLC cut its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 20.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,609,114 shares of the company's stock after selling 652,279 shares during the quarter. Eliem Therapeutics makes up about 2.6% of Samsara BioCapital LLC's investment portfolio, making the stock its 9th biggest position. Samsara BioCapital LLC owned about 8.77% of Eliem Therapeutics worth $13,280,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new stake in Eliem Therapeutics in the second quarter worth about $134,000. Rhumbline Advisers acquired a new position in Eliem Therapeutics in the 2nd quarter valued at $59,000. Dimensional Fund Advisors LP acquired a new position in shares of Eliem Therapeutics in the 2nd quarter valued at $89,000. Renaissance Technologies LLC lifted its position in shares of Eliem Therapeutics by 248.5% during the second quarter. Renaissance Technologies LLC now owns 37,000 shares of the company's stock worth $263,000 after purchasing an additional 26,383 shares in the last quarter. Finally, Ally Bridge Group NY LLC acquired a new stake in Eliem Therapeutics in the second quarter valued at approximately $3,555,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.
Eliem Therapeutics Trading Down 1.9 %
Shares of NASDAQ ELYM traded down $0.06 during mid-day trading on Thursday, reaching $3.09. The company had a trading volume of 105,395 shares, compared to its average volume of 486,688. The stock has a market cap of $91.93 million, a P/E ratio of -5.83 and a beta of -0.39. Eliem Therapeutics, Inc. has a 52-week low of $2.35 and a 52-week high of $11.55. The firm has a 50 day simple moving average of $4.19 and a two-hundred day simple moving average of $6.29.
About Eliem Therapeutics
(
Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
See Also
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
